• Edwards Lifesciences won FDA clearance for its AUTUS size-adjustable surgical pulmonary valve for pediatric congenital heart disease patients.
• The device can be expanded later via a transcatheter procedure, aiming to reduce repeat open-heart surgeries as children grow.
• Approval was supported by a pivotal study showing 100% freedom from device-related complications at 30 days, no reinterventions through six months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edwards Lifesciences Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202610011626BIZWIRE_USPR_____20261001_BW568896) on October 01, 2026, and is solely responsible for the information contained therein.